Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Assets (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Assets data on record, last reported at $2.9 billion in Q4 2025.

  • For Q4 2025, Assets rose 70.01% year-over-year to $2.9 billion; the TTM value through Dec 2025 reached $2.9 billion, up 70.01%, while the annual FY2025 figure was $2.9 billion, 70.01% up from the prior year.
  • Assets reached $2.9 billion in Q4 2025 per PTCT's latest filing, up from $2.6 billion in the prior quarter.
  • Across five years, Assets topped out at $2.9 billion in Q4 2025 and bottomed at $1.3 billion in Q3 2023.
  • Average Assets over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2023.
  • Peak YoY movement for Assets: fell 25.83% in 2023, then skyrocketed 70.01% in 2025.
  • A 5-year view of Assets shows it stood at $1.9 billion in 2021, then fell by 11.99% to $1.7 billion in 2022, then increased by 11.14% to $1.9 billion in 2023, then decreased by 10.06% to $1.7 billion in 2024, then surged by 70.01% to $2.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $2.9 billion in Q4 2025, $2.6 billion in Q3 2025, and $2.6 billion in Q2 2025.